The Archer® FusionPlex® Myeloid Kit is a targeted next-generation sequencing assay to detect and identify fusions, point mutations and expression levels from 84 genes associated with myeloid-origin malignancies. Studies are performed from RNA extracted from several types of starting sample. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this kit can be identified in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.
Chronic Myeloid Leukemia
ABL1 (ABL proto-oncogene 1), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ASXL1 (ASXL Transcriptional Regulator 1), BCR (BCR Activator Of RhoGEF And GTPase), BRAF (B-raf proto-oncogene), CALR (Calreticulin)
See More ...
Next-Generation Sequencing (NGS)